PIM1 Antikörper

Produktnummer ABIN6944550

Produktdetails anti-PIM1 Antikörper

Target: PIM1 (Pim-1 Oncogene (PIM1))

Reaktivität: Human, Maus

Wirt: Kaninchen

Klonalität: Monoklonal

Konjugat: Dieser PIM1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (Cultured Cells) (IF (cc))

Kreuzreaktivität: Human, Maus

Aufreinigung: Purified by Protein A.

Immunogen: Human PIM1 between 1-100 amino acids

Klon: 5A12

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB 1:300-5000
IHC-P 1:200-400
IF(ICC) 1:50-200

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 1xTBS ( pH 7.4), 1 % BSA, 40 %Glycerol and 0.05 % Sodium Azide.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20°C for 12 months.

Haltbarkeit: 12 months

Details zu PIM1

Target: PIM1 (Pim-1 Oncogene (PIM1))

Andere Bezeichnung: PIM1 (PIM1 Produkte)

Synonyme: PIM antikoerper, Pim-1 antikoerper, PIM1 antikoerper, pim antikoerper, pim-1 antikoerper, pim3 antikoerper, Pim-1 proto-oncogene, serine/threonine kinase antikoerper, proviral integration site 1 antikoerper, Pim-1 proto-oncogene, serine/threonine kinase L homeolog antikoerper, PIM1 antikoerper, Pim1 antikoerper, pim1 antikoerper, pim1.L antikoerper

Hintergrund:

Synonyms: Serine/threonine-protein kinase pim-1, PIM1

Background: Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation and thus providing a selective advantage in tumorigenesis. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression and by phosphorylation and inhibition of proapoptotic proteins (BAD, MAP3K5, FOXO3). Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase of transcriptional activity. The stabilization of MYC exerted by PIM1 might explain partly the strong synergism between these two oncogenes in tumorigenesis. Mediates survival signaling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl-X(L)/BCL2L1. Phosphorylation of MAP3K5, an other proapoptotic protein, by PIM1, significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis. Stimulates cell cycle progression at the G1-S and G2-M transitions by phosphorylation of CDC25A and CDC25C. Phosphorylation of CDKN1A, a regulator of cell cycle progression at G1, results in the relocation of CDKN1A to the cytoplasm and enhanced CDKN1A protein stability. Promote cell cycle progression and tumorigenesis by down-regulating expression of a regulator of cell cycle progression, CDKN1B, at both transcriptional and post-translational levels. Phosphorylation of CDKN1B,induces 14-3-3-proteins binding, nuclear export and proteasome-dependent degradation. May affect the structure or silencing of chromatin by phosphorylating HP1 gamma/CBX3. Acts also as a regulator of homing and migration of bone marrow cells involving functional interaction with the CXCL12-CXCR4 signaling axis.

Gen-ID: 5292

UniProt: P11309

Pathways: Glycosaminoglycan Metabolic Process